Literature DB >> 835506

Nutrient intake of treated infants with phenylketonuria.

P B Acosta, E Wenz, M Williamson.   

Abstract

Growth, energy, and nutrient intake of 88 treated infants in the Collaborative Study of Children Treated for Phenylketonuria were evaluated longitudinally and compared to normative data and by treatment group. Growth parameters (height and weight) did not differ according to treatment group assignment, nor did they differ from normative data. Subjects in treatment group 2 had a significantly higher intake of phenylalanine than did subjects in treatment group 1. Differences in intake of other nutrients disappeared when intake was compared on an energy or body weight basis. Differences in intake by males and females also disappeared when compared on an energy and a body weight basis. From none to 10% of the subjects had energy intakes below two-thirds of the 1968 Recommended Dietary Allowances (RDA). Low individual energy intakes were more commonly found in the first and fourth quarters, and only during the first quarter of infancy did mean energy intake meet the RDA. From 48 to 80% of subjects had intakes of preformed niacin below two-thirds of the 1968 RDA. Few subjects had low intakes of protein, iron, or vitamin A, and intakes of all subjects were greater than 67% of the RDA for calcium, phosphorus, thiamin, riboflavin, and ascorbic acid. It is suggested from the data presented that a supplemental casein hydrolysate supplies adequate essential amino acids and nitrogen to support normal growth in infants when protein and energy intakes are fed at the levels described.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 835506     DOI: 10.1093/ajcn/30.2.198

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  9 in total

1.  The intake of total protein, natural protein and protein substitute and growth of height and head circumference in Dutch infants with phenylketonuria.

Authors:  M Hoeksma; M Van Rijn; P H Verkerk; A M Bosch; M F Mulder; J B C de Klerk; T J de Koning; E Rubio-Gozalbo; M de Vries; P J J Sauer; F J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

Authors:  S Yannicelli; D M Medeiros
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

3.  Recommendations for protein and amino acid intake in phenylketonuric patients.

Authors:  F Cockburn; B J Clark
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

4.  Recommendations for protein and energy intakes by patients with phenylketonuria.

Authors:  P B Acosta
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

5.  Zinc status and growth of children undergoing treatment for phenylketonuria.

Authors:  P B Acosta; P M Fernhoff; H S Warshaw; L J Elsas; K M Hambidge; A Ernest; E R McCabe
Journal:  J Inherit Metab Dis       Date:  1982       Impact factor: 4.982

Review 6.  Dietary interventions for phenylketonuria.

Authors:  Vanessa J Poustie; Joanne Wildgoose
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

7.  Dietary interventions for phenylketonuria.

Authors:  Elisabeth Jameson; Tracey Remmington
Journal:  Cochrane Database Syst Rev       Date:  2020-07-16

Review 8.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

9.  Problems related to diet management of maternal phenylketonuria.

Authors:  P B Acosta; S Stepnick-Gropper
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.